Abiomed, Inc.
ABMD · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $11 | $11 | $15 | $16 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $11 | $11 | $15 | $16 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -4.1% | 2.7% | 3.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 81.6% | 81% | 80.9% | 81.8% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 85% | 28.9% | 34% | 27.4% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 39.9% | 19.7% | 22.4% | 17.5% |
| EPS Diluted | 2.32 | 1.19 | 1.31 | 1 |
| % Growth | 95% | -9.2% | 31% | – |
| Operating Cash Flow | $0 | $0 | $0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | $0 | $0 | $0 |